Research

Energy balance

From 2015 to 2019, the percentage of T2D patients treated with a GLP-1 RA increased from 3.2% to 10.7%.

Healthcare providers should be aware of the increasing adoption of GLP-1 RAs among T2D patients.

StrongSupportsmedium confidence
From 2015 to 2019, the percentage of T2D patients treated with an GLP-1 RA increased from 3.2% to 10.7%.
Lauren A. Eberly et al. · JAMA Health Forum · 2021

Why this rating

Based on a retrospective cohort analysis of a large patient population.

Source

Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US

Lauren A. Eberly et al. · JAMA Health Forum · 2021

DOI 10.1001/jamahealthforum.2021.4182

cohort · n=1180260Cited 259×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →